Gilead Misses Mark on Earnings as Daniel O'Day Prepares to Take Helm
This article is for subscribers only.
Gilead Sciences Inc. posted fourth-quarter earnings that missed expectations as the biotechnology giant fends off threats to its best-selling drugs and prepares for a new CEO to take the reins.